Els M E Verdegaal
Overview
Explore the profile of Els M E Verdegaal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borgers J, van Wesemael T, Gelderman K, Rispens T, Verdegaal E, Moes D, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38945553
Introduction: Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could...
2.
Groeneveldt C, Kinderman P, Griffioen L, Rensing O, Labrie C, van den Wollenberg D, et al.
Cancer Immunol Res
. 2024 Jan;
12(3):334-349.
PMID: 38194598
Reovirus type 3 Dearing (Reo), manufactured for clinical application as pelareorep, is an attractive anticancer agent under evaluation in multiple phase 2 clinical trials for the treatment of solid tumors....
3.
Verdegaal E, Santegoets S, Welters M, de Bruin L, Visser M, van der Minne C, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 37949617
Background: The presence of T cells and suppressive myeloid cells in epithelial ovarian cancer (EOC) correlate with good and bad clinical outcome, respectively. This suggests that EOC may be sensitive...
4.
de Rooij M, Remst D, van der Steen D, Wouters A, Hagedoorn R, Kester M, et al.
Mol Ther Oncolytics
. 2023 Nov;
31:100738.
PMID: 37920174
[This corrects the article DOI: 10.1016/j.omto.2022.11.007.].
5.
van den Bulk J, Verdegaal E, van der Ploeg M, Visser M, Nunes J, de Ru A, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4278-4288.
PMID: 37540567
Purpose: The availability of (neo)antigens and the infiltration of tumors by (neo)antigen-specific T cells are crucial factors in cancer immunotherapy. In this study, we aimed to investigate the targetability of...
6.
van Amerongen R, Tuit S, Wouters A, van de Meent M, Siekman S, Meeuwsen M, et al.
Front Immunol
. 2023 Apr;
14:1121973.
PMID: 37026005
Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic 'cold'...
7.
van den Bulk J, van der Ploeg M, Ijsselsteijn M, Ruano D, van der Breggen R, Duhen R, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36792124
Background: Expression of CD103 and CD39 has been found to pinpoint tumor-reactive CD8 T cells in a variety of solid cancers. We aimed to investigate whether these markers specifically identify...
8.
de Rooij M, Remst D, van der Steen D, Wouters A, Hagedoorn R, Kester M, et al.
Mol Ther Oncolytics
. 2023 Jan;
28:1-14.
PMID: 36589698
To increase the number of cancer patients that can be treated with T cell receptor (TCR) gene therapy, we aimed to identify a set of high-affinity cancer-specific TCRs targeting different...
9.
Harryvan T, de Lange S, Hawinkels L, Verdegaal E
Int J Mol Sci
. 2022 Jan;
23(1).
PMID: 35008560
Professional antigen-presenting cells (APCs), such as dendritic cells and macrophages, are known for their ability to present exogenous antigens to T cells. However, many other cell types, including endothelial cells,...
10.
Hurkmans D, Verdegaal E, Hogan S, de Wijn R, Hovestad L, van den Heuvel D, et al.
J Immunother Cancer
. 2021 Jan;
8(2).
PMID: 33427690
Background: Many cancer patients do not obtain clinical benefit from immune checkpoint inhibition. Checkpoint blockade targets T cells, suggesting that tyrosine kinase activity profiling of baseline peripheral blood mononuclear cells...